Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Stuart Pocock, Peter E. Carson, James L. Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann, Waheed Jamal, Karen A. Kimura, Janet M. Schnee, Cordula Zeller, Daniel Cotton, Edimar Alcides Bocchi, Michael Böhm, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Stefan P. Janssens, Jian Zhang, José Ramón González‐Juanatey, Sanjay Kaul, Hans‐Peter Brunner‐La Rocca, Béla Péter Merkely, Stephen James Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr P. Ponikowski, Naveed A. Sattar, Michele Senni, Marie‐France Seronde, Jindřich Špinar, Iain B Squire, Stefano Taddei, Christoph Wanner, Faiez M. Zannad
New England Journal of Medicine · 2020 · 5,468 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Carson, P. E., Januzzi, J. L., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K. A., Schnee, J. M., Zeller, C., Cotton, D., Bocchi, E. A., Böhm, M., Choi, D., Chopra, V., … Zannad, F. M. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413–1424. https://doi.org/10.1056/nejmoa2022190
In text: (Packer et al., 2020)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODSIn this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy.The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTSDuring a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001).The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes.The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001).The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28ml per minute per 1.73 m 2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes.Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONSAmong patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.(Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.govnumber, NCT03057977.
Related papers
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus1993
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin2002
- International Diabetes Federation 20172018
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015
- Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance2001
Metadata from OpenAlex (CC0). Citations are generated from the published record.